NAUTNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31

Nautilus Biotechnology, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026

$2.63+0.57 (+27.67%)

Close on Oct 19, 2026

Market cap: $334.37M
P/E (TTM): –
Dividend yield: –

Nautilus Biotechnology, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Research & Development	41	50	47	38	29	12
General & Administrative	26	31	29	26	21	3.31
Operating Expenses	67	81	76	64	50	16
Other Non-Operating Income	7.84	11	12	5.69	0.18	0.13
Asset Impairment Charges	0	0	0	0	0	0
Gain (Loss) on Sale of Assets	–	-0.08	0	0	-0.14	-0.01
Income Tax Expense	0	0	0	0	0	0
Net Income	-59	-71	-64	-58	-50	-16
Net Income to Common	-59	-71	-64	-58	-50	-16
EPS (Basic)(per share)	-0.47	-0.56	-0.51	-0.46	-0.60	-0.54
EPS (Diluted)(per share)	-0.47	-0.56	-0.51	-0.46	-0.60	-0.54
Shares Outstanding (Basic, Weighted)(shares)	126	125	125	125	84	29
Shares Outstanding (Diluted, Weighted)(shares)	126	125	125	125	84	29

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -32.3%

Financial strength

Current ratio: 10.14
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 152.4%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 2.55
Dividend yield: –